News 07.12.2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), has today announced...
News 05.12.2025 Zurich, Switzerland - 04.12.2025 Neurimmune today announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, AstraZeneca Rare Disease by entering into an exclusive global collaboration and license agreement to develop NI009, a preclinical human monoclonal antibody designed to target and deplete lambda light chain fibrils and deposits...
News 03.12.2025 CUTISS is pleased to share that the 1-year results of the Phase IIb clinical trial evaluating denovoSkin™ in adolescent and adult burn patients have been published in eClinicalMedicine, part of The Lancet Discovery Science. The prospective, randomized, controlled multicenter study compared denovoSkin™ to split-thickness skin grafts, the current surgical standard. The...
News 02.12.2025 Schlieren (Zürich), Switzerland, December 2, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced that the first patient has been enrolled in its global ASTRA (Ankle Subtalar arThrodesis Randomized Assessment) study. ASTRA is a prospective, randomized, single-blinded, controlled, multi-center study to assess the...
News 21.11.2025 CUTISS has been awarded 2nd place at the 2025 edition of The Spark – Der Deutsche Digitalpreis, which recognizes outstanding deep-tech innovation across Germany, Austria, and Switzerland. The award ceremony in Munich brought together finalists from across a range of industries. CUTISS was recognized for its pioneering work in personalized regenerative...